^
Association details:
| Biomarker: | BCL2 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study
Excerpt:
...- Patients with MYC and BCL2 co-expression Diffuse Large B-Cell Lymphoma diagnosed by histopathologyImmunohistochemistry confirmed that the positive expression rate of BCL-2≥50% and c-Myc≥ 40%....
Trial ID:
Source:
Title:
Lenalidomide maintenance therapy in elderly patients with high-risk diffuse large B-cell lymphoma
Excerpt:
...The presence of one of the following poor prognostic factors: (1) IPI score >= 2 points; (2) Double expression of BCL-2/MYC; (3) non-GCB subtype; (4) >=2 extranodal lesions; (5) Bone marrow involvement; (6) CD5+; (7) ki-67 >=80%; (8) Genetic testing has MYD88, CD79B, NOTCH1 and other unfavorable prognosis mutations; (9) 6-cycle R-CHOP efficacy did not reach CR. ...
Trial ID:
Less C2 evidence
Source:
Title:
2950 Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial
Published date:
11/03/2022
Excerpt:
Histologic diagnosis of DLBCL and MYC/BCL-2 expression by IHC were confirmed...Fifty-seven patients responded to therapy, with overall response rate of 95% (57/60), and complete response rate of 80% (48/60). With a median follow-up of 17.8 months, the estimated 1-year PFS rate was 85.3% (95%CI 75.9%-95.2%). And the 1-year EFS rate was 79% (95%CI 68.8%-90.3%)....Our preliminary data indicate promising activity of lenalidomide combined with R-CHOP for newly diagnosed DEL patients.
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.1182/blood-2022-158657
